Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Regulatory
177 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Abiraterone | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Accord is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. | approved | Apr 26, 2021 | ema |
| Abiraterone | EU EMA | Castration-Resistant Prostate Carcinoma | Zytiga is indicated with prednisone or prednisolone for: the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.accelerated | approved | Sep 5, 2011 | ema |
| Abiraterone | US FDA | Castration-Resistant Prostate Carcinoma | Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) |
Data updated 5 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Olaparib | 58 | 58 | 0 |
| Cisplatin | 24 | 9 | 14 |
| Erdafitinib | 22 | 20 | 2 |
| Rucaparib | 21 | 21 | 0 |
| Enzalutamide | 20 | 8 | 12 |
| Carboplatin | 17 | 9 | 8 |
| Abiraterone | 14 | 3 | 11 |
| Paclitaxel | 14 | 6 | 7 |
| Everolimus | 13 | 11 | 2 |
| Chemotherapy | 12 | 12 | 0 |
| Talazoparib | 12 | 12 | 0 |
| Palbociclib | 8 | 7 | 1 |
| Platinum Compound |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| approved |
| May 22, 2018 |
| openfda |
| Abiraterone Acetate | EU EMA | Malignant Prostate Neoplasm | Treatment of adult patients with prostate cancer. | approved | Apr 19, 2023 | ema |
| Abiraterone Acetate | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Mylan is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. | approved | Aug 20, 2021 | ema |
| Abiraterone Acetate | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Krka is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. | approved | Jun 24, 2021 | ema |
| Abiraterone Acetate | US FDA | Castration-Resistant Prostate Carcinoma | Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) | approved | May 22, 2018 | openfda |
| Aldesleukin | US FDA | Renal Cell Carcinoma | The treatment of adults with metastatic renal cell carcinoma. | approved | May 5, 1992 | openfda |
| Apalutamide | EU EMA | Nonmetastatic Castration-Resistant Prostate Carcinoma | Erleada is indicated: in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). | approved | Jan 14, 2019 | ema |
| Apalutamide | US FDA | Nonmetastatic Castration-Resistant Prostate Carcinoma | ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. ( 1 ) non-metastatic castration-resistant prostate cancer. ( 1 ) | approved | Feb 14, 2018 | openfda |
| Atezolizumab | US FDA | Malignant Bladder Neoplasm | Muscle Invasive Bladder Cancer (MIBC) as adjuvant treatment of adult patients with MIBC after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test. | approved | May 18, 2016 | openfda |
| Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor | EU EMA | Malignant Prostate Neoplasm | Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. | withdrawnsince May 6, 2015 | Sep 6, 2013 | ema |
| Avelumab | US FDA | Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. | approved | Mar 23, 2017 | openfda |
| Avelumab | US FDA | Urothelial Carcinoma | Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. | approved | Mar 23, 2017 | openfda |
| Axitinib | EU EMA | Renal Cell Carcinoma | Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. | approved | Sep 19, 2024 | ema |
| Axitinib | EU EMA | Renal Cell Carcinoma | Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. | approved | Sep 3, 2012 | ema |
| Axitinib | US FDA | Renal Cell Carcinoma | as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. | approved | Jan 27, 2012 | openfda |
| Axitinib | US FDA | Renal Cell Carcinoma | in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). | approved | Jan 27, 2012 | openfda |
| Belzutifan | US FDA | Clear Cell Renal Cell Carcinoma | as monotherapy, for treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). | approved | Aug 13, 2021 | openfda |
| Belzutifan | US FDA | Clear Cell Renal Cell Carcinoma | Renal Cell Carcinoma with a Clear Cell Component (ccRCC) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the adjuvant treatment of adult patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. | approved | Aug 13, 2021 | openfda |
| Bevacizumab | US FDA | Malignant Cervical Neoplasm | Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Renal Cell Carcinoma | Metastatic renal cell carcinoma in combination with interferon alfa. | approved | Feb 26, 2004 | openfda |
| Bicalutamide | US FDA | Prostate Carcinoma | 1. INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2) ]. Bicalutamide tablets 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. (1) Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments. (1) | approved | Oct 4, 1995 | openfda |
| Cabazitaxel | EU EMA | Malignant Prostate Neoplasm | Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. | approved | Aug 28, 2020 | ema |
| Cabazitaxel | EU EMA | Malignant Prostate Neoplasm | Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. | approved | Mar 17, 2011 | ema |
| Cabazitaxel | US FDA | Castration-Resistant Prostate Carcinoma | JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 ) | approved | Jun 17, 2010 | openfda |
| Cabozantinib | EU EMA | Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell carcinoma as first-line treatment of adult patients with intermediate or poor risk, in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Hepatocellular carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.Differentiated thyroid carcinoma (DTC)Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.Neuroendocrine Tumours (NET)Cabometyx is indicated for the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues.accelerated | approved | Sep 9, 2016 | ema |
| Cabozantinib | US FDA | Renal Cell Carcinoma | CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). | approved | Apr 25, 2016 | openfda |
| Cabozantinib | US FDA | Renal Cell Carcinoma | patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab | approved | Apr 25, 2016 | openfda |
| Capivasertib | US FDA | Malignant Prostate Neoplasm | PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer • in combination with abiraterone and prednisone for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer that is PTEN-deficient as detected by an FDA-authorized test. | approved | Nov 16, 2023 | openfda |
| Carboplatin | US FDA | Ovarian Carcinoma | As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy. | approved | Aug 8, 2025 | openfda |
| Carboplatin | US FDA | Ovarian Carcinoma | As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. | approved | Aug 8, 2025 | openfda |
| Cisplatin | US FDA | Malignant Bladder Neoplasm | INDICATIONS Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. | approved | Dec 19, 1978 | openfda |
| Cyclophosphamide | US FDA | Ovarian Adenocarcinoma | adenocarcinoma of the ovary | approved | Sep 12, 2023 | openfda |
| Dabrafenib | US FDA | Tumor-agnostic | the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated | approved | Mar 16, 2023 | openfda |
| Dabrafenib | US FDA | Tumor-agnostic | the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated | approved | May 29, 2013 | openfda |
| Dactinomycin | US FDA | Malignant Testicular Neoplasm | adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. | approved | Nov 9, 2017 | openfda |
| Darolutamide | EU EMA | Nonmetastatic Castration-Resistant Prostate Carcinoma | NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1). | approved | Mar 27, 2020 | ema |
| Darolutamide | US FDA | Nonmetastatic Castration-Resistant Prostate Carcinoma | NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. | approved | Jul 30, 2019 | openfda |
| Degarelix | EU EMA | Malignant Prostate Neoplasm | Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated: for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer. | approved | Sep 29, 2023 | ema |
| Degarelix | EU EMA | Malignant Prostate Neoplasm | FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer. | approved | Feb 17, 2009 | ema |
| Degarelix | US FDA | Malignant Prostate Neoplasm | FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 ) | approved | Dec 24, 2008 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Mar 25, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Feb 13, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. | approved | Mar 5, 2024 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Jun 1, 2010 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC | approved | Nov 22, 2022 | openfda |
| 8 |
| 7 |
| 1 |
| Temsirolimus | 8 | 7 | 1 |
| Trastuzumab | 7 | 7 | 0 |
| Lapatinib | 6 | 6 | 0 |
| Pazopanib | 6 | 5 | 1 |
| Bevacizumab | 5 | 4 | 1 |
| Cetuximab | 5 | 3 | 2 |
| Sunitinib | 5 | 2 | 2 |
| Trametinib | 5 | 5 | 0 |
| Afatinib | 4 | 4 | 0 |
| Atezolizumab | 4 | 4 | 0 |
| Dasatinib | 4 | 4 | 0 |
| Docetaxel | 4 | 3 | 1 |
| Doxorubicin | 4 | 2 | 2 |
| Erlotinib | 4 | 3 | 1 |
| MTOR Inhibitor | 4 | 4 | 0 |
| Niraparib | 4 | 4 | 0 |
| PD173074 | 4 | 4 | 0 |
| Pembrolizumab | 4 | 4 | 0 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| Bicalutamide | 3 | 0 | 3 |
| Cabazitaxel | 3 | 2 | 1 |
| Capivasertib | 3 | 2 | 1 |
| Dinaciclib | 3 | 3 | 0 |
| Dovitinib | 3 | 3 | 0 |
| Futibatinib | 3 | 2 | 1 |
| Infigratinib | 3 | 3 | 0 |
| Linsitinib | 3 | 3 | 0 |
| Nivolumab | 3 | 3 | 0 |
| Pictilisib | 3 | 3 | 0 |
| Ridaforolimus | 3 | 2 | 1 |
| Abiraterone Acetate | 2 | 0 | 2 |
| Akt Inhibitor MK2206 | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Cediranib | 2 | 2 | 0 |
| Decitabine | 2 | 2 | 0 |
| Dostarlimab | 2 | 2 | 0 |
| Eprenetapopt | 2 | 2 | 0 |
| Fexagratinib | 2 | 2 | 0 |
| Gemcitabine | 2 | 1 | 0 |
| Imatinib | 2 | 2 | 0 |
| Immune Checkpoint Inhibitor | 2 | 1 | 1 |
| Ipatasertib | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Pemetrexed | 2 | 2 | 0 |
| Pertuzumab | 2 | 2 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 2 | 2 | 0 |
| Sirolimus | 2 | 1 | 1 |
| Sorafenib | 2 | 1 | 1 |
| Taxane Compound | 2 | 1 | 1 |
| Vemurafenib | 2 | 2 | 0 |
| Abemaciclib | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| Alpelisib | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Anti-PD1 Monoclonal Antibody | 1 | 1 | 0 |
| Anti-PD-L1 Monoclonal Antibody | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| Asparaginase | 1 | 0 | 1 |
| ATR Inhibitor | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AZD-4547 | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Binimetinib | 1 | 1 | 0 |
| Bosutinib | 1 | 1 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 1 | 1 | 0 |
| Carboplatin/Paclitaxel Regimen | 1 | 1 | 0 |
| CDK Inhibitor SNS-032 | 1 | 1 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 1 | 1 | 0 |
| Crizotinib | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Dabrafenib | 1 | 1 | 0 |
| Durvalumab | 1 | 1 | 0 |
| Entrectinib | 1 | 0 | 1 |
| Etoposide | 1 | 0 | 1 |
| EZH2 Inhibitor | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| Foretinib | 1 | 1 | 0 |
| Fulvestrant | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Ganitumab | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| Immunotherapy | 1 | 1 | 0 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| Ipilimumab | 1 | 1 | 0 |
| Irinotecan | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| Larotrectinib | 1 | 1 | 0 |
| Lonafarnib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Metformin | 1 | 1 | 0 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 1 | 1 | 0 |
| Navtemadlin | 1 | 1 | 0 |
| Neratinib | 1 | 1 | 0 |
| Nilutamide | 1 | 0 | 1 |
| Panitumumab | 1 | 0 | 1 |
| Picoplatin | 1 | 0 | 1 |
| Ponatinib | 1 | 1 | 0 |
| Prednisone | 1 | 1 | 0 |
| Quisinostat | 1 | 1 | 0 |
| R3Mab | 1 | 0 | 1 |
| Ribociclib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| Selumetinib | 1 | 1 | 0 |
| Seribantumab | 1 | 1 | 0 |
| Taselisib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Tipifarnib | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
| Veliparib | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.